ES2870596T3 - Inmunoterapia basada en indolamina 2,3-dioxigenasa - Google Patents

Inmunoterapia basada en indolamina 2,3-dioxigenasa Download PDF

Info

Publication number
ES2870596T3
ES2870596T3 ES17194619T ES17194619T ES2870596T3 ES 2870596 T3 ES2870596 T3 ES 2870596T3 ES 17194619 T ES17194619 T ES 17194619T ES 17194619 T ES17194619 T ES 17194619T ES 2870596 T3 ES2870596 T3 ES 2870596T3
Authority
ES
Spain
Prior art keywords
ido
hla
cells
peptide
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17194619T
Other languages
English (en)
Spanish (es)
Inventor
Mads Hald Andersen
Per Thor Straten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Application granted granted Critical
Publication of ES2870596T3 publication Critical patent/ES2870596T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
ES17194619T 2008-04-17 2009-04-17 Inmunoterapia basada en indolamina 2,3-dioxigenasa Active ES2870596T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200800565 2008-04-17

Publications (1)

Publication Number Publication Date
ES2870596T3 true ES2870596T3 (es) 2021-10-27

Family

ID=40873320

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17194619T Active ES2870596T3 (es) 2008-04-17 2009-04-17 Inmunoterapia basada en indolamina 2,3-dioxigenasa
ES09753556.1T Active ES2657963T3 (es) 2008-04-17 2009-04-17 Inmunoterapia basada en indolamina 2,3-dioxigenasa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09753556.1T Active ES2657963T3 (es) 2008-04-17 2009-04-17 Inmunoterapia basada en indolamina 2,3-dioxigenasa

Country Status (20)

Country Link
US (7) US9433666B2 (OSRAM)
EP (3) EP3915570A1 (OSRAM)
JP (2) JP2011520783A (OSRAM)
CN (2) CN102088994B (OSRAM)
AU (1) AU2009253539B2 (OSRAM)
CA (1) CA2721150C (OSRAM)
CY (2) CY1120352T1 (OSRAM)
DK (2) DK3320912T3 (OSRAM)
ES (2) ES2870596T3 (OSRAM)
HR (2) HRP20180282T1 (OSRAM)
HU (2) HUE055338T2 (OSRAM)
IL (1) IL208781A (OSRAM)
LT (2) LT3320912T (OSRAM)
NO (1) NO2280721T3 (OSRAM)
NZ (1) NZ588757A (OSRAM)
PL (2) PL3320912T3 (OSRAM)
PT (2) PT2280721T (OSRAM)
SI (2) SI2280721T1 (OSRAM)
WO (1) WO2009143843A1 (OSRAM)
ZA (1) ZA201008056B (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180282T1 (hr) 2008-04-17 2018-03-23 Io Biotech Aps Imunoterapija na bazi indoleamin 2, 3-dioksigenaze
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
CA2947650C (en) * 2014-05-29 2021-04-27 Spring Bioscience Corporation Anti- indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof
EP3193917B9 (en) 2014-09-17 2022-02-16 IO Biotech ApS Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
CN106148276A (zh) * 2015-04-16 2016-11-23 中国科学院上海生命科学研究院 间充质干细胞在制备治疗神经退行性疾病的药物中的应用
KR20180021882A (ko) 2015-06-29 2018-03-05 오제 이뮈노테라프틱스 짧은 펩타이드 항-암 백신을 이용하여 초기 t 기억 반응을 유도하는 방법
JP6924747B2 (ja) 2015-09-16 2021-08-25 アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ Ｃ−ｃモチーフケモカイン２２（ｃｃｌ２２）またはこのフラグメントを含むワクチン組成物
FI3423087T3 (fi) 2016-03-04 2023-12-15 Io Biotech Aps Syövän vastainen yhdistelmähoito
JP2019517544A (ja) 2016-06-10 2019-06-24 アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ Ｃａｌｒ及びｊａｋ２ワクチン組成物
CA3039364A1 (en) * 2016-10-04 2018-04-12 University Of Florida Research Foundation, Inc. Targeted effector proteins and uses thereof
CN110249056A (zh) * 2016-10-14 2019-09-17 苏黎世大学 用于前列腺癌诊断及预后的吲哚胺-2,3-双加氧酶检测
BR112019014406A2 (pt) * 2017-01-20 2020-04-28 Atara Biotherapeutics Inc métodos de tratar esclerose múltipla usando células t autólogas
CR20210130A (es) * 2017-01-27 2021-03-31 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de càncer (divisional exp. 2019-388)
WO2018138257A1 (en) * 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
US11407797B2 (en) 2017-10-11 2022-08-09 University Of Florida Research Foundation, Incorporated Modified gal-1 proteins and uses thereof
KR102624844B1 (ko) 2017-11-27 2024-01-12 오제 이뮈노테라프틱스 암의 향상된 치료
CN109758467B (zh) * 2019-03-08 2020-12-25 中国农业科学院兰州兽医研究所 一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用
JP2022554217A (ja) * 2019-10-23 2022-12-28 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 養子免疫療法
CA3188581A1 (en) * 2020-07-02 2022-01-06 The Regents Of The University Of California Persistent memory t-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways
CN112881269A (zh) * 2021-02-23 2021-06-01 浙江正熙生物技术股份有限公司 一种流式荧光检测试剂的质量检测方法
GB202103673D0 (en) 2021-03-17 2021-04-28 Io Biotech Aps Combination therapy for cancer
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
CN114657158B (zh) * 2022-05-25 2022-10-21 深圳吉诺因生物科技有限公司 Ido1相关疫苗及其应用
US20240238384A1 (en) * 2023-01-17 2024-07-18 Regeneron Pharmaceuticals, Inc. Treatment Of B27-Negative Uveitis With Inositol Polyphosphate Multikinase (IPMK) Therapeutic Agents Or Indoleamine 2,3-dioxygenase 2 (IDO2) Agonists
WO2024178160A2 (en) * 2023-02-21 2024-08-29 Salvitus, Inc. Recombinant phage, probiotic vaccines and therapeutics, related compositions and methods of use
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
BR9608804A (pt) * 1995-06-20 1999-02-17 Merck & Co Inc Processos para sintetizar (1s,2r) indandiol para sintetizar (1s) amino (2r) indanol substancialmente isento de qualquer estereoisômero de bio-resolução para remover cis (1s,2r) indandiol de uma mistura de cis (1s,2r) indandiol e cis (1r,2s) indandiol e cultura pura
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
EP0956046A4 (en) 1996-06-12 2004-10-20 Yajun Guo CELLULAR VACCINALS AND IMMUNOTHERAPEUTICS AND METHOD FOR THE PRODUCTION THEREOF
CN1223688A (zh) * 1996-06-27 1999-07-21 纳幕尔杜邦公司 对羟基苯丙酮酸双加氧酶的植物基因
DE19730066A1 (de) * 1997-07-14 1999-01-21 Basf Ag DNA-Sequenz codierend für eine Hydroxyphenylpyruvatdioxygenase und deren Überproduktion in Pflanzen
AU1628599A (en) 1997-12-05 1999-06-28 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan
AU4697600A (en) 1999-05-03 2000-11-17 Ludwig Institute For Cancer Research Methods for increasing t cell proliferation
JP2005503760A (ja) 2001-01-24 2005-02-10 プロテイン デザイン ラブス， インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
AU2002258518A1 (en) 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20030148316A1 (en) 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
EP2177601A1 (en) 2002-04-12 2010-04-21 Medical College of Georgia Research Institute, Inc Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
US7763251B2 (en) 2002-04-12 2010-07-27 Medical College Of Georgia Research Institute, Inc. Kits to assess the risk of tumor progression
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
WO2004048938A2 (en) 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004053075A2 (en) 2002-12-05 2004-06-24 Diadexus, Inc. Compositions, splice variants and methods relating to breast specific genes and proteins
JP2006511532A (ja) 2002-12-13 2006-04-06 ミトラ、メディカル、テクノロジー、アクチボラグ 三官能性試薬によって連結された、エフェクター機能および親和性機能を有する抗リンパ腫ターゲティング剤
DE10261223A1 (de) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
EP2260846B1 (en) 2003-03-27 2018-11-28 Lankenau Institute for Medical Research Novel methods for the treatment of cancer
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
US20050186289A1 (en) 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
WO2005017163A2 (en) 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
WO2005036127A2 (en) 2003-10-02 2005-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying target cell cytolytic lymphocytes in a sample
EP2130826A1 (en) * 2004-07-13 2009-12-09 The University of British Columbia Annulins A, B, C or analogs as indoleamine 2,3-dioxygenase (IDO) inhibitors for treatment of cancer
WO2006056304A2 (en) 2004-11-23 2006-06-01 Institut Pasteur Control of indoleamine 2,3 deoxygenase expression and activity
CA2593714C (en) 2005-02-04 2013-09-10 Survac Aps Survivin peptide vaccine
ME02461B (me) 2005-05-10 2017-02-20 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
US7468186B2 (en) 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
WO2007039150A2 (en) * 2005-09-23 2007-04-12 Cellerix, S.L. Cell populations having immunoregulatory activity, method for isolation and uses
WO2007095050A2 (en) 2006-02-09 2007-08-23 Incyte Corporation N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
WO2007115068A2 (en) 2006-03-30 2007-10-11 Indiana University Research And Technology Corporation Genetic variants in the indoleamine 2,3-dioxygenase gene
WO2008143668A2 (en) * 2006-05-18 2008-11-27 Lankenau Institute For Medical Research Indoleamine-2, 3-dioxygenase-2
WO2008085828A2 (en) * 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
HRP20180282T1 (hr) 2008-04-17 2018-03-23 Io Biotech Aps Imunoterapija na bazi indoleamin 2, 3-dioksigenaze

Also Published As

Publication number Publication date
CN104056261A (zh) 2014-09-24
US20170049868A1 (en) 2017-02-23
CA2721150A1 (en) 2009-12-03
SI3320912T1 (sl) 2021-08-31
US20190201512A1 (en) 2019-07-04
CY1120352T1 (el) 2019-07-10
EP3320912B1 (en) 2021-03-31
EP2280721A1 (en) 2011-02-09
AU2009253539A1 (en) 2009-12-03
ES2657963T3 (es) 2018-03-07
US20220249641A1 (en) 2022-08-11
CN102088994A (zh) 2011-06-08
IL208781A (en) 2017-09-28
US20220202922A1 (en) 2022-06-30
EP3320912A1 (en) 2018-05-16
NO2280721T3 (OSRAM) 2018-04-14
ZA201008056B (en) 2011-07-27
NZ588757A (en) 2012-05-25
PL2280721T3 (pl) 2018-04-30
US20110318372A1 (en) 2011-12-29
HRP20180282T1 (hr) 2018-03-23
US10258678B2 (en) 2019-04-16
HUE055338T2 (hu) 2021-11-29
US20250319159A1 (en) 2025-10-16
US12233103B2 (en) 2025-02-25
US20230233657A1 (en) 2023-07-27
JP2015129182A (ja) 2015-07-16
SI2280721T1 (en) 2018-02-28
CN104056261B (zh) 2017-01-11
CY1124279T1 (el) 2022-07-22
CA2721150C (en) 2017-09-26
AU2009253539B2 (en) 2014-03-20
EP3915570A1 (en) 2021-12-01
CN102088994B (zh) 2014-06-25
JP6016966B2 (ja) 2016-10-26
JP2011520783A (ja) 2011-07-21
PT2280721T (pt) 2018-02-16
US11324813B2 (en) 2022-05-10
DK2280721T3 (da) 2018-01-29
LT2280721T (lt) 2018-02-12
LT3320912T (lt) 2021-07-12
US9433666B2 (en) 2016-09-06
US11648302B2 (en) 2023-05-16
HUE037973T2 (hu) 2018-09-28
DK3320912T3 (da) 2021-05-31
EP2280721B1 (en) 2017-11-15
HRP20210766T1 (hr) 2021-07-23
WO2009143843A1 (en) 2009-12-03
PL3320912T3 (pl) 2021-10-25
PT3320912T (pt) 2021-05-24
IL208781A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
ES2870596T3 (es) Inmunoterapia basada en indolamina 2,3-dioxigenasa
JP7491965B2 (ja) ネオ抗原およびその使用方法
CN112584852A (zh) 新抗原及其用途
CN112638404A (zh) 新抗原及其用途
JP2022551918A (ja) マルチドメインタンパク質ワクチン
JP6811710B2 (ja) トリプトファン２，３−ジオキシゲナーゼまたはそのフラグメントを含むワクチン組成物
HK1247114B (en) Indoleamine 2, 3-dioxygenase based immunotherapy
RU2773273C2 (ru) Неоантигены и способы их использования
HK40050845A (en) Neoantigens and uses thereof
HK40050847A (en) Neoantigens and uses thereof